Format

Send to

Choose Destination
Blood. 2014 Nov 6;124(19):2983-6. doi: 10.1182/blood-2014-07-584953. Epub 2014 Sep 15.

Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.

Author information

1
Service d'Anatomie et Cytologie Pathologiques, Centre Hospitalier Universitaire, Hôtel Dieu, Nantes, France;
2
Swiss Institute of Bioinformatics, Bȃtiment Genopode, Lausanne, Switzerland;
3
Département de Pathologie, Hôpital Pessac, Bordeaux, France;
4
Département de Pathologie, Hôpital Purpan, Toulouse, France;
5
Unité Hémopathies Lymphoïdes, Groupe Henri Mondor Albert-Chenevier, Assistance Publique - Hôpitaux de Paris, Créteil, France;
6
Service d'Anatomie et Cytologie Pathologiques, Hôpital Avicenne, Bobigny, France;
7
Département d'Anatomie Pathologique, Hôpital Saint Antoine, Assistance Publique - Hôpitaux de Paris, Paris, France;
8
Service d'Hématologie, Hôpital Necker, Assistance Publique - Hôpitaux de Paris, Paris, France;
9
Service de Thérapie Cellulaire et d'Hématologie Clinique Adulte, Université d'Auvergne, Inserm Centre d'Investigation Clinique 501, Centre Hospitalier Universitaire Clermont-Ferrand Hôpital Estaing, Clermont-Ferrand, France;
10
Swiss Institute of Bioinformatics, Bȃtiment Genopode, Lausanne, Switzerland; Ludwig Center for Cancer Research, and Oncology Department, University of Lausanne, Lausanne, Switzerland;
11
Département de Pathologie, Groupe Henri-Mondor Albert-Chenevier, Assistance Publique - Hôpitaux de Paris, Créteil, France; Inserm U955, Créteil, France; Université Paris Est, Créteil, France; and.
12
Institut de Pathologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Abstract

The extended use of brentuximab-vedotin was reported for CD30(+) nonanaplastic peripheral T-cell lymphomas (PTCLs) with promising efficacy. CD30 status assessment is thus a critical factor for therapeutic decision, but the reliability of immunohistochemistry (IHC) in evaluating its expression remains to be defined. This prompted us to investigate the correlation between semiquantitative CD30 protein assessment by IHC and messenger RNA (mRNA) assessment by microarrays in a cohort of 376 noncutaneous PTCLs representative of the main entities. By IHC, CD30 expression was heterogeneous across and within entities and significantly associated with large tumor cell size. In addition to 100% anaplastic large-cell lymphomas, 57% of other PTCL entities were CD30-positive at a 5% threshold. CD30 protein expression was highly correlated to mRNA levels. mRNA levels were bimodal, separating high from low CD30-expressing PTCL cases. We conclude that IHC is a valuable tool in clinical practice to assess CD30 expression in PTCLs.

PMID:
25224410
DOI:
10.1182/blood-2014-07-584953
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center